These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 26991242

  • 1. Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.
    Wager TT, Hou X, Verhoest PR, Villalobos A.
    ACS Chem Neurosci; 2016 Jun 15; 7(6):767-75. PubMed ID: 26991242
    [Abstract] [Full Text] [Related]

  • 2. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT, Hou X, Verhoest PR, Villalobos A.
    ACS Chem Neurosci; 2010 Jun 16; 1(6):435-49. PubMed ID: 22778837
    [Abstract] [Full Text] [Related]

  • 3. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.
    Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y.
    ACS Chem Neurosci; 2010 Jun 16; 1(6):420-34. PubMed ID: 22778836
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY, Liu H, Summerfield SG, Luscombe CN, Sahi J.
    Mol Pharm; 2016 May 02; 13(5):1540-50. PubMed ID: 27015243
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Assessment of the classification abilities of the CNS multi-parametric optimization approach by the method of logistic regression.
    Raevsky OA, Polianczyk DE, Mukhametov A, Grigorev VY.
    SAR QSAR Environ Res; 2016 Aug 02; 27(8):629-35. PubMed ID: 27477321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparing the Pfizer Central Nervous System Multiparameter Optimization Calculator and a BBB Machine Learning Model.
    Urbina F, Zorn KM, Brunner D, Ekins S.
    ACS Chem Neurosci; 2021 Jun 16; 12(12):2247-2253. PubMed ID: 34028255
    [Abstract] [Full Text] [Related]

  • 14. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A.
    Chem Biodivers; 2009 Nov 16; 6(11):2030-49. PubMed ID: 19937839
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond.
    Odi R, Bibi D, Wager T, Bialer M.
    Epilepsia; 2020 Aug 16; 61(8):1543-1552. PubMed ID: 32614073
    [Abstract] [Full Text] [Related]

  • 19. Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by P-glycoprotein.
    Dolghih E, Jacobson MP.
    ACS Chem Neurosci; 2013 Feb 20; 4(2):361-7. PubMed ID: 23421687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.